logo

Biotech Daily Dose

Share

pharma-daily-051718.jpg Today's Daily Dose brings you news about Anika's accelerated share repurchase program; Esperion's phase III study results of bempedoic acid in patients with hypercholesterolemia; TherapeuticsMD and Teva's near-term catalysts.

pharma-daily-052218.jpg Today's Daily Dose brings you news about FDA approval of AstraZeneca's hyperkalemia drug; Dova's platelet booster Doptelet getting regulatory nod; the fifth indication for Amgen's Prolia securing thumbs-up; Sesen's encouraging three-month data from the VISTA trial and investors' concern and Nabriva's LEAP 2 study results.

pharma-daily-051718.jpg Another week has gone by, and it was raining FDA approvals. Now, here are some of the pharma/biotech stocks and upcoming events to keep an ear out for in the coming week.

pharma-daily-051618.jpg Today's Daily Dose brings you news about Agios Pharma's upcoming catalysts; Evolus' disappointment over FDA rejection of DWP-450 for treatment of moderate to-severe glabellar lines; promising data of Immunomedics' investigational Sacituzumab govitecan in metastatic breast cancer.

pharma-daily-051618.jpg Today's Daily Dose brings you news about FDA approval of the first and only biosimilar erythropoiesis-stimulating agent in the U.S., Titan Pharma's better-than-expected Q1 results; Sol-Gel's clinical trial catalysts; Xenon Pharma's positive phase I interim data of epilepsy drug candidate XEN1101, and Lilly's phase III data of migraine drug candidate Galcanezumab.

pharma-051518.jpg Today's Daily Dose brings you news about ProPhase Labs' first quarter financial results; Soleno's progress in Prader-Willi Syndrome program; ADMA's upcoming milestones; Dicerna's near-term catalyst, and Coherus' regulatory catalyst in November.

pharma-calendar-051018.jpg It's been an action-packed week with announcements of a number of FDA approvals, a couple of Big Pharma names failing in late-stage trials, and two acquisitions. Let's take a look at the pharma stocks and upcoming events to keep an ear out for in the coming week.

pharma-daily-051018.jpg Today's Daily Dose brings you news about FDA panel's stance on Akcea's drug candidate for a rare lipid disorder called familial chylomicronemia syndrome; ViewRay's better-than expected first-quarter results; Synergy Pharma's lackluster Q1 TRULANCE sales; Regulus' pipeline update and BioLife's record revenue for the first quarter of 2018.

pharma-daily-042618.jpg Today's Daily Dose brings you news about Aquinox's licensing agreement for Rosiptor; Asterias' progress in SCiStar study; Arcus' upcoming milestones; Catalyst Pharma's near-term catalysts; Invitae's solid financial results for 1Q, and FDA rejection of Lipocine's oral testosterone product candidate TLANDO for the second time.

pharma-daily-050818.jpg Today's Daily Dose brings you news about Akcea's regulatory catalyst to watch out for on Wednesday, Alder's near-term catalysts; Aralez Pharma shutting up shop in the U.S.; Foamix's progress in phase III acne study; Tactile Systems' stellar results and upbeat outlook; Natera's improved Q1 financial results, and Reata Pharma's upcoming milestones.

pharma-daily2-050718.jpg Today's Daily Dose brings you news about FDA approval of Astellas Pharma's Myrbetriq/VESIcare combo for overactive bladder; MediciNova's progress in MN-166 in alcohol dependence and withdrawal; regulatory nod for expanded use of DARZALEX; Ultragenyx Pharma's near-term catalysts; solid financial results of Misonix and Xencor's upcoming clinical trial plans.

pharma-daily-042618.jpg Today's Daily Dose brings you news about FDA panel shooting down Mallinckrodt's pharmacologic treatment for neonatal jaundice; Sarepta's partnership with Myonexus for developing gene therapies for Limb-Girdle Muscular Dystrophies; FDA approval of Portola's antidote, and Dermira's upcoming milestones.

pharma-daily-042618.jpg Today's Daily Dose brings you news about FDA panel's vote on Achaogen's Plazomicin; Karyopharm's public offering; Cellectis' progress in TALEN gene-edited product pipeline; Globus Medical's Q1 financial results; a federal Court's ruling, which has gone in favor of Progenics/Valeant, and Esperion's pivotal phase III long-term safety study results of Bempedoic acid.

pharma-daily-05-02-2018.jpg Today's Daily Dose brings you news about FDA panel backing for SIGA's smallpox drug; Karyopharm's public offering; Veracyte's rosy outlook; Retrophin's upcoming milestones and expansion of VIVUS' commercial product portfolio.

pharma-daily-042618.jpg Today's Daily Dose brings you news about Apellis Pharma's upcoming clinical trial catalysts; Conatus' progress in ENCORE-PH study; CE Mark approval of Edwards Cardioband Tricuspid Valve Reconstruction System; Inogen's rosy outlook; Karyopharm's STORM data, and Q1 results of MEDNAX and Orthofix International.

Follow RTT